A nano-diagnostic agent and its preparation method and application
By polymerizing the small molecule cyanine dye IR-1064 with acrylamide and 2-methacryloyloxyethylphosphorylcholine on the surface to form a nanodiagnostic agent, the photothermal conversion of existing NIR-IIb photosensitizers is solved. The problems of low efficiency and poor biocompatibility achieve efficient imaging and treatment of deep tumors.
Patent Information
- Application Number
- CN202310184592.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-01
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-03-01
AI Technical Summary
The existing NIR-IIb photosensitizer has low photothermal conversion efficiency and poor biocompatibility, making it difficult to achieve efficient imaging and treatment of deep tissue lesions.
The J-type aggregate of the small-molecular cyanine dye IR-1064 is polymerized with acrylamide and 2-methacryloyloxyethylphosphorylcholine on the surface to form a spherical nanodiagnostic agent with a diameter of 50±4nm, through static electricity The combination of effects improves its photothermal conversion efficiency and biocompatibility in the NIR-IIb range.
It realizes high-efficiency imaging within the NIR-IIb range and photothermal therapy of deep tumors, can cross the blood-brain barrier, has good targeting and stability, and is suitable for multimodal imaging and treatment.
Smart Images

Figure CN116350601B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical nanomaterials, and in particular to a nano diagnostic and therapeutic agent and a preparation method and application thereof. Background Art
[0002] Imaging in the near-infrared region II (NIR-II), especially the 1500-1700nm biological window (NIR-IIb), is a new imaging method that significantly improves the imaging resolution by reducing the absorption, scattering and autofluorescence of light. A large number of studies have shown that NIR-IIb imaging can effectively improve the signal-to-noise ratio and penetration depth, and has little toxicity and side effects on the body. In recent years, it has attracted more and more attention from scientists. Among them, organic small molecule cyanine dyes have become a hot spot in NIR-IIb imaging research due to their good biocompatibility, high fluorescence quantum yield and easy functional modification of the structure. However, most of the current small molecule cyanine dyes have their maximum absorption in the near-infrared region I (NIR-I) and have poor water solubility and photostability, making it difficult to achieve true NIR-IIb high-resolution and deep-level tissue lesion imaging.
[0003] Photothermal therapy is a new treatment for tumors. It mainly involves injecting materials with high photothermal conversion efficiency into the living body and using an external light source to convert light energy into heat energy, thereby inhibiting or killing tumor cells. Currently, most NIR-IIb photosensitizers have low photothermal conversion efficiency and poor biocompatibility, are easily photobleached, and have no targeting, which limits their effectiveness in tumor treatment. Therefore, it is urgent to develop new NIR-IIb photothermal conversion materials that are tumor-targeted and easily degradable.
[0004] Therefore, the prior art still needs to be improved and developed. Summary of the invention
[0005] In view of the above-mentioned deficiencies in the prior art, the purpose of the present invention is to provide a nano-diagnostic and therapeutic agent with maximum absorption and emission in NIR-IIb, and a preparation method and application thereof, aiming to provide a new NIR-IIb photosensitizer to solve the problems of imaging and treatment of deep tissue lesions.
[0006] The technical solution of the present invention is as follows:
[0007] A nano-diagnostic and therapeutic agent, comprising: a J-type aggregate of a small molecule cyanine dye IR-1064, and a polymer bound to the surface of the J-type aggregate of the small molecule cyanine dye IR-1064, wherein the polymer is obtained by in situ polymerization of acrylamide and 2-methacryloyloxyethyl phosphorylcholine on the surface of the J-type aggregate of the small molecule cyanine dye IR-1064.
[0008] Furthermore, the J-type aggregate of the small molecule cyanine dye IR-1064 and the polymer are combined through electrostatic interaction.
[0009] Furthermore, the nano-diagnostic and therapeutic agent is a spherical particle with a diameter of 50±4nm.
[0010] Furthermore, the surface of the nano-diagnostic and therapeutic agent is positively charged.
[0011] A method for preparing the nano diagnostic and therapeutic agent according to the present invention, comprising the steps of:
[0012] The small molecule cyanine dye IR-1064 is self-assembled to form a J-type aggregate of the small molecule cyanine dye IR-1064;
[0013] The acrylamide and 2-methacryloyloxyethyl phosphorylcholine are made to undergo in-situ polymerization reaction on the surface of the J-type aggregate of the small molecule cyanine dye IR-1064 to obtain the nano diagnostic and therapeutic agent.
[0014] Furthermore, the preparation method of the nano diagnostic and therapeutic agent specifically comprises the steps of:
[0015] Dissolving a small molecule cyanine dye IR-1064 in water, performing a first stirring under heating conditions, and then performing a first centrifugation to obtain a J-type aggregate of the small molecule cyanine dye IR-1064;
[0016] Acrylamide, 2-methacryloyloxyethyl phosphorylcholine and the J-type aggregate of the small molecule cyanine dye IR-1064 are mixed in water, and then ammonium persulfate and tetramethylethylenediamine are added under a second stirring to carry out an in situ polymerization reaction on the surface of the J-type aggregate of the small molecule cyanine dye IR-1064, and finally the nano-diagnostic and therapeutic agent is obtained through a second centrifugation.
[0017] Further, the temperature of the in-situ polymerization reaction is 4°C, and the time of the in-situ polymerization reaction is 2.5h;
[0018] The mass ratio of the small molecule cyanine dye IR-1064, acrylamide, ammonium persulfate, tetramethylethylenediamine, and 2-methacryloyloxyethyl phosphorylcholine is 1: (0.05-0.1): (0.1-0.5): (0.1-0.5): (1-5).
[0019] Further, the heating temperature is 60°C; the first stirring speed is 500 rpm;
[0020] The first centrifugation speed is 4500 rpm and the centrifugation time is 15 min.
[0021] Further, the mixing method is vortex;
[0022] The speed of the second stirring is 500 rpm;
[0023] The second centrifugation speed is 4500 rpm and the centrifugation time is 15 min.
[0024] A use of the nano diagnostic and therapeutic agent as described in the present invention in the preparation of a tumor diagnostic and therapeutic preparation.
[0025] Beneficial effects: The nano-diagnostic and therapeutic agent of the present invention is a complex of a J-type aggregate of a small molecule cyanine dye (denoted as LET-12') and a polymer (obtained by in situ polymerization of BIS and MPC on the surface of LET-12'), wherein LET-12' and the MPC in the polymer have good electrostatic binding ability, thereby enabling the polymer to bind to LET-12'. The nano-diagnostic and therapeutic agent can cross the blood-brain barrier (BBB) to achieve in situ imaging and treatment of brain gliomas. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 This is the structural formula and H NMR spectrum of the small molecule cyanine dye IR-1064.
[0027] Figure 2 This is the structural formula and high-resolution mass spectrum of the small molecule cyanine dye IR-1064.
[0028] Figure 3 Schematic diagram of the synthesis process of the nano-diagnostic and therapeutic agent of the present invention.
[0029] Figure 4 Figure 1 is the UV absorption graph of LET-12 before and after synthesis; Figure 2 is the fluorescence emission spectrum of LET-12 before and after synthesis;
[0030] Figure 5 Figure 1 is a graph showing the zeta potential change of LET-12 in Example 2 of the present invention; Figure 2 is a graph showing the particle size change; and Figure 3 is a 7-day stability test.
[0031] Figure 6 Figure 1 is the fluorescence imaging diagram of LET-12 under different filters in Example 3 of the present invention; Figure 2 is the fluorescence imaging diagram of LET-12 of different concentrations under different filters; Figure 3 is the fluorescence quantification curve; Figure 4 is the fluorescence imaging diagram of LET-12 at different depths; Figure 5 is the fluorescence quantification curve; and Figure 6 is the capillary width quantification curve.
[0032] Figure 7 The photoacoustic imaging and quantification diagram of LET-12 of different concentrations in Example 4 of the present invention.
[0033] Figure 8 1 is the photothermal cycle diagram of LET-12 in Example 5 of the present invention; 2 is the photothermal conversion efficiency of LET-12.
[0034] Fig. 9 Figure 1 is the UV absorption graph of cells in the LET-12 group in Example 6 of the present invention; Figure 2 is the UV absorption graph of cells in the LET-12' group; and Figure 3 is the UV absorption quantification graph of cells in different drug treatment groups.
[0035] Fig.10 Figure 1 is a graph showing cell survival rates of different drug-treated groups without illumination in Example 7 of the present invention; Figure 2 is a graph showing cell survival rates of illuminated groups.
[0036] Fig.11 Figure 1 is a fluorescence imaging image of mouse brain tumors in different treatment groups in Example 8 of the present invention; Figure 2 is a photoacoustic imaging image of mouse brain tumors; Figure 3 is a fluorescence imaging intensity quantification image of mouse brain tumors; and Figure 4 is a photoacoustic imaging signal intensity quantification image of mouse brain tumors.
[0037] Fig.12 Figure 1 is the photothermal heating curve of the mouse brain tumor in Example 9 of the present invention; Figure 2 is the survival rate of the mouse; Figure 3 is the quantification curve of the spontaneous fluorescence intensity; and Figure 4 is the in situ terminal transferase labeling staining of the tumor tissue. DETAILED DESCRIPTION
[0038] The present invention provides a nano-diagnostic agent and a preparation method and application thereof. To make the purpose, technical solution and effect of the present invention clearer and more specific, the present invention is further described in detail below. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.
[0039] The present invention provides a nano diagnostic and therapeutic agent, which includes: a J-type aggregate of a small molecule cyanine dye IR-1064, and a polymer located on the surface of the J-type aggregate of the small molecule cyanine dye IR-1064, wherein the polymer is obtained by in situ polymerization of acrylamide (BIS) and 2-methacryloyloxyethyl phosphorylcholine (MPC) on the surface of the J-type aggregate of the small molecule cyanine dye IR-1064.
[0040] Combination Figure 3As shown, the inventors discovered for the first time that the small molecule cyanine dye IR-1064 can self-assemble to form a J-type aggregate with an absorption greater than 1400nm and a maximum emission greater than 1500nm. The J-type aggregate of the small molecule cyanine dye IR-1064 is recorded as LET-12'. In situ polymerization is carried out on the surface of the LET-12' using BIS and MPC to obtain the nano-diagnostic agent (LET-12). The polymer generated by polymerization is combined with the LET-12' through electrostatic action, because the MPC in the polymer and LET-12' have good electrostatic binding ability. Among them, MPC can be used as a carrier for LET-12 to cross the blood-brain barrier, which is beneficial to improve the ability of LET-12 to cross the blood-brain barrier, and can also change the charge on the surface of the nanoparticles, which is beneficial to the enrichment of nano-diagnostic agents in deep-seated tumors in the brain; LET-12 can be used as a contrast agent and photosensitizer, and can achieve NIR-IIb deep-seated tumor imaging and treatment under laser irradiation.
[0041] Furthermore, the nano-diagnostic and therapeutic agent is a spherical particle with a diameter of 50±4 nm. Nanoparticles within this particle size range have high BBB crossing ability and high permeability and retention (EPR) effect of solid tumors.
[0042] The present invention provides a method for preparing the nano diagnostic and therapeutic agent as described above, which comprises the steps of:
[0043] The small molecule cyanine dye IR-1064 is self-assembled to form a J-type aggregate of the small molecule cyanine dye IR-1064;
[0044] The acrylamide and 2-methacryloyloxyethyl phosphorylcholine are made to undergo in-situ polymerization reaction on the surface of the J-type aggregate of the small molecule cyanine dye IR-1064 to obtain the nano diagnostic and therapeutic agent.
[0045] The nano-diagnostic agent of the present invention is a small molecule cyanine dye IR-1064 that first self-assembles to form a J-type aggregate LET-12', and then BIS and MPC undergo an in-situ polymerization reaction on the surface of LET-12' nanoparticles to obtain the nano-diagnostic agent (LET-12). The nano-diagnostic agent can simultaneously achieve NIR-IIb multimodal imaging of in-situ gliomas and photothermal therapy under the guidance of multimodal imaging. Specifically, the phosphorylcholine group in the polymer generated by polymerization crosses the BBB through endocytosis and exocytosis mediated by acetylcholine receptors on the walls of cerebral blood vessels, thereby achieving imaging and treatment of in-situ brain gliomas. In addition, the structure of the MPC is similar to that of the neurotransmitters choline and acetylcholine, and attachment to the surface of LET-12' can achieve imaging and treatment of deep-level in-situ brain gliomas.
[0046] The present invention utilizes the good electrostatic binding ability of the J-type aggregate (LET-12') of the small molecule cyanine dye and MPC, so that the J-type aggregate LET-12' of the small molecule cyanine dye is combined with the polymer to obtain the nano diagnostic and therapeutic agent (LET-12). The nano diagnostic and therapeutic agent can realize NIR-IIb imaging and photothermal therapy of in situ brain glioma. The nano diagnostic and therapeutic agent can be delivered to the tumor site for imaging-guided photothermal therapy of the tumor. The nano diagnostic and therapeutic agent is simple to prepare, can be mass-produced, and is easy to realize industrialization, and has good application prospects in the field of tumor treatment.
[0047] Furthermore, the preparation method of the nano diagnostic and therapeutic agent specifically comprises the steps of:
[0048] The small molecule cyanine dye IR-1064 is dissolved in water, first stirred under heating conditions, and then first centrifuged to obtain LET-12';
[0049] BIS, MPC and LET-12' are mixed evenly in water, and then catalysts ammonium persulfate (APS) and tetramethylethylenediamine (TEMED) are added under a second stirring to carry out an in-situ polymerization reaction on the surface of LET-12'. After the reaction is completed, the nano-diagnostic agent (LET-12) is obtained by a second centrifugation.
[0050] The present invention firstly self-assembles the small molecule cyanine dye IR-1064 to form spherical nanoparticles having J-type aggregate characteristics, that is, the small molecule cyanine dye IR-1064 self-assembles to obtain LET-12'; then BIS and MPC undergo in-situ polymerization reaction on the surface of LET-12' nanoparticles to obtain the LET-12.
[0051] Furthermore, the mass ratio of the small molecule cyanine dye IR-1064, acrylamide, ammonium persulfate, tetramethylethylenediamine, and 2-methacryloyloxyethyl phosphorylcholine is 1: (0.05-0.1): (0.1-0.5): (0.1-0.5): (1-5). The mass ratio of the small molecule cyanine dye IR-1064 and MPC is 1: (1-5), which can better improve the ability of LET-12' to cross the BBB, thereby achieving better therapeutic effects.
[0052] Furthermore, the mass ratio of the small molecule cyanine dye IR-1064, acrylamide, ammonium persulfate, tetramethylethylenediamine, and 2-methacryloyloxyethyl phosphorylcholine is 1:0.074:0.296:0.1508:2.
[0053] Furthermore, the temperature of the in-situ polymerization reaction is 4° C., and the time of the in-situ polymerization reaction is 2.5 h.
[0054] Furthermore, the heating temperature is 60°C.
[0055] Furthermore, the first stirring speed is 500 rpm.
[0056] Furthermore, the first centrifugation speed is 4500 rpm and the centrifugation time is 15 min.
[0057] Furthermore, the mixing method is vortexing.
[0058] Furthermore, the second stirring speed is 500 rpm.
[0059] Furthermore, the second centrifugation speed is 4500 rpm and the centrifugation time is 15 min.
[0060] An application of the nano diagnostic and therapeutic agent of the present invention in the preparation of a tumor diagnostic and therapeutic preparation.
[0061] The nano-diagnostic and therapeutic agent of the present invention can also be used together with other drugs to prepare a preparation for diagnosing and treating tumors. The application of the nano-diagnostic and therapeutic agent in tumor diagnostic and therapeutic agents, wherein the tumor treatment is photothermal therapy guided by NIR-IIb imaging.
[0062] The nano-diagnostic agent prepared by the preparation method of the present invention can realize the photothermal treatment of deep-seated tumors guided by NIR-IIb imaging, and thus has good application prospects in the field of tumor treatment. At the same time, the preparation process of the present invention is simple, easy to operate, does not require complex and expensive equipment, and is easy to realize industrial production.
[0063] The present invention will be further described below by means of specific examples.
[0064] Example 1: Synthesis of LET-12 Nanotheranostic Agent
[0065] IR-1064 (2 μmol) was dissolved in a mixed solution of 6 mL ultrapure water and DMSO (DMSO volume ratio was 4%) and stirred at 60 °C for 45 min. After cooling, it was filtered with a 220 nm filter and collected. The filter was washed three times with ultrapure water to remove free IR-1064. Finally, the obtained LET-12' was dissolved in ultrapure water to obtain a concentration of 1 mg mL -1 1 mL of LET-12' solution (1 mg mL -1 ) and 1 mL MPC solution (concentration 2 mg mL -1 , the solvent is ultrapure water), 1 mL BIS solution (concentration is 0.074 mg mL -1, the solvent is ultrapure water) by vortex mixing. Then add 1 mL of APS solution (concentration 0.296 mg mL -1 , the solvent is ultrapure water) and 1 mL of TEMED solution (concentration is 0.1508 mg mL -1 The mixture was kept at 4°C for 2.5 hours to complete the polymerization, and then the polymerized solution was dialyzed to obtain the nano-diagnostic agent LET-12. The potential of LET-12' and LET-12 was measured using a Zeta potential meter.
[0066] The structural formula and H NMR spectrum of small molecule cyanine dye IR-1064 are shown in Figure 1 shown.
[0067] The structural formula and high-resolution mass spectrometry of the small molecule cyanine dye IR-1064 are shown in Figure 2 shown.
[0068] The UV spectrum of synthesized LET-12' is shown in Figure 4 As shown in 1. Figure 4 From 1 in the figure, we can know that the maximum absorption of the synthesized LET-12' is located at 1400nm. The UV absorption and fluorescence emission spectra of the synthesized nano-diagnostic agent LET-12 are shown in Figure 4 As shown in Figures 1 and 2, it can be seen that the maximum absorption and maximum emission of the synthesized nano-diagnostic agent are located at 1400nm and 1500nm respectively.
[0069] First, it should be noted that LET-12' and LET-12 in the following Examples 2-9 are synthesized in Example 1.
[0070] Example 2: Zeta potential and DLS analysis of synthetic nanotheranostic agent (LET-12)
[0071] The Zeta potential of LET-12' and LET-12 was detected by Zeta potential instrument. The particle size of LET-12' and LET-12 was detected by DLS, as well as the particle size of LET-12 in H2O, PBS, FBS and DMEM for 7 consecutive days.
[0072] The Zeta potential diagram of the synthesized nano-theranostic agent (LET-12) is shown in Figure 5 As shown in 1. Figure 5 As shown in Figure 1, LET-12' is negatively charged (about -25 mV) and LET-12 is positively charged (about 2.4 mV). Figure 5 As shown in Figure 2, the particle size of LET-12' is about 36±2nm, and the particle size of LET-12 is about 50±4nm. The stability of the synthesized nano-theranostic agent (LET-12) in different solvents is shown in Figure 2. Figure 5 As shown in Figure 3, LET-12 was distributed in H2O, PBS, FBS and DMEM, and its particle size remained basically stable within 7 days, indicating that the formed nanoparticles were the product of the combination of LET-12' and MPC and had good stability.
[0073] Example 3: Evaluation of LET-12 near infrared IIb region (NIR-IIb) fluorescence imaging performance
[0074] The effect of different treatments on the fluorescence properties of LET-12 was evaluated using a near-infrared two-zone imaging system. -1 )、LET-12'(10μg mL -1 ) and LET-12 (10 μg mL -1 ) were filled in a 250 μL centrifuge tube and irradiated with a 1064 nm laser under different long-pass filters (1100, 1200, 1300, 1400 and 1500 nm) to measure the fluorescence signal intensity. -1 ) were filled in a 96-well plate, and the relationship between the fluorescence signal intensity and the concentration of the nano-diagnostic agent under different long-pass filters (1100, 1200, 1300, 1400 and 1500 nm) was measured. -1 ) were placed in 1% fat emulsion at different depths, and then imaged using a bandpass filter with a wavelength of 1500 nm to measure the fluorescence signals at different depths.
[0075] The imaging results of synthesized IR-1064, LET-12' and nano-diagnostic agent LET-12 under filters of different lengths are shown in Figure 2. Figure 6 As shown in Figure 1, LET-12' and the nano-diagnostic agent LET-12 can still be clearly imaged under a 1500nm long-pass filter. Therefore, LET-12' and the nano-diagnostic agent LET-12 have excellent NIR-IIb fluorescence imaging performance. The imaging diagram of the fluorescence intensity and concentration of LET-12 under different concentrations and filters of different lengths is shown in Figure 1. Figure 6 As shown in 2, the quantization diagram is as follows Figure 6 As shown in 3, according to Figure 6 2 and 3, the fluorescence imaging signal intensity of LET-12 has a good linear relationship with the concentration of LET-12. Figure 6 As shown in Figure 4, the quantification of the change of fluorescence intensity with depth is shown in Figure 6 As shown in Figure 5, the thickness of the capillary changes with imaging depth. Figure 6 As shown in Figure 6, Figure 6As shown in Figures 4, 5 and 6, the fluorescence signal gradually decreases with increasing depth and the capillary gradually becomes thinner, but its maximum penetration depth can reach 3.0 mm, proving that the nano-diagnostic agent LET-12 has excellent NIR-IIb fluorescence imaging performance and high-resolution imaging performance of deep tissues.
[0076] Example 4: Evaluation of LET-12 near infrared IIb region (NIR-IIb) fluorescence imaging performance
[0077] The Vevo LAZR-X system equipped with a 1275 nm pulsed laser was used to measure the concentrations of different concentrations (0-250 μg mL -1 ) for imaging with LET-12. Figure 7 As shown, the photoacoustic imaging signal intensity of LET-12 has a good linear relationship with the concentration of LET-12, proving that the nano-diagnostic agent LET-12 has good photoacoustic imaging performance.
[0078] Example 5: Evaluation of the photothermal effect of LET-12
[0079] Thermal imaging was used to evaluate the photothermal stability and photothermal conversion efficiency of LET-12. -1 ) was filled in a centrifuge tube (250 μL) and irradiated with a 1064 nm laser (0.6 W cm -2 ) for 5 min, cooled for 9 min, and then cycled for 5 times. Photothermal conversion efficiency of LET-12: To obtain the cooling curve, LET-12 (62.5 μg mL -1 ) was filled in a centrifuge tube (250 μL) and irradiated with a 1064 nm laser (0.6 W cm -2 ) for 12 minutes and cooled for 10 minutes. The light and heat stability test results of LET-12 are as follows Figure 8 As shown in Figure 1, after five cycles of heating and cooling, the maximum temperature remains unchanged. The results of the photothermal conversion efficiency are shown in Figure 1. Figure 8 As shown in Figure 2, its photothermal conversion efficiency can reach 47.1%. The exploration of the photothermal properties of LET-12 shows that LET-12 has good photothermal properties and high photothermal conversion efficiency and can be used as a photosensitizer.
[0080] Example 6: Effect of time on intracellular uptake of LET-12.
[0081] The uptake of LET-12 by cells was measured by detecting the change of maximum UV absorption over time. 4Cells / well) were seeded in 96-well plates for 24 h. -1 ) were added to U87MG-Luc cells and incubated for 12 h. The culture medium was then removed and the cells were further washed with PBS three times to remove free LET-12 and LET-12', and cell lysates were prepared with cell lysis buffer (RIPA buffer) to measure the corresponding absorption. The uptake of LET-12 in cells over time is shown in Fig. 9 As shown in Figure 1, the UV absorption of cell lysate gradually increased with the increase of time and reached the maximum at 12h. Fig. 9 As shown in Figure 2, the trend is similar to that of LET-12. The uptake of LET-12 and LET-12' in cells is quantified as shown in Fig. 9 As shown in Figure 3, the absorption of LET-12' in cells is slightly lower than that of LET-12, which may be caused by the large amount of negative charges on the surface of LET-12'.
[0082] Example 7: Evaluation of the effects of LET-12 and LET-12' on cell activity under different conditions
[0083] U87MG-Luc cells (5×10 4 Cells / well) were seeded in 96-well plates and incubated at 37°C, 5% CO2 for 24 h. -1 ) were added to U87MG-Luc cells and cultured for 12 hours. Then, the old culture medium in the 96-well plate was aspirated, and 100 μL of MTT culture medium solution was added to each well. The culture was continued for 4 hours. Then, the MTT-containing culture medium in the 96-well plate was carefully aspirated, and 150 μL of DMSO solution was added to each well. After gentle shaking, the OD value of each well was detected on a Synergy H1 microplate reader (detection wavelength was 490 nm). The cell survival rate was calculated using the following formula. Cell survival rate (%) = (OD value of sample) 570 Value / BlankOD 570 value)×100%.
[0084] U87MG-Luc cells (5×10 4 Cells / well) were inoculated in 96-well plates and incubated for 24 h. -1) were added to the cells and incubated for another 12 h. The old medium in the 96-well plate was aspirated and the wells were washed three times with PBS. -2 Finally, the standard MTT assay was tested.
[0085] The results of the dark toxicity test of LET-12 and LET-12' on cells are as follows Fig.10 As shown in Figure 1, after 12 hours of cell culture, the cell activity of LET-12 group remained above 90%, while the cell activity of LET-12' group was slightly lower than that of LET-12 group. This may be because LET-12' has a large amount of negative charge on its surface, which is slightly toxic to cells. The test results of LET-12 and LET-12' on the phototoxicity of cells are shown in Figure 1. Fig.10 As shown in Figure 2, after illumination, the cell activities of LET-12 and LET-12' groups were both lower than 20%, proving that the material has a good photothermal killing effect on cells.
[0086] Example 8: Evaluation of the NIR-II imaging effect of LET-12 in vivo.
[0087] LET-12 and LET-12' (10 mg kg -1 ) were intravenously injected into orthotopic U87MG-Luc tumor-bearing mice, and the FL / PA signal changes of the mice were then monitored in real time using the NIR-II FL / PA imaging system.
[0088] NIR-IIb mouse head was originally used for fluorescence imaging of brain glioma Fig.11 As shown in Figure 1, the head of the NIR-IIb mouse was originally a glioma photoacoustic imaging Fig.11 As shown in Figure 2, the mouse head was originally a brain glioma. The fluorescence intensity quantification diagram is as follows Fig.11 As shown in Figure 3, the mouse head was originally a brain glioma. The photoacoustic intensity quantification image is as follows Fig.11 As shown in Figure 4, the above results demonstrate that the LET-12 molecule has excellent imaging effect in NIR-II, can cross the blood-brain barrier and achieve maximum enrichment inside the tumor within 12 hours.
[0089] Example 9: Evaluation of the photothermal therapeutic effect of LET-12 in vivo.
[0090] The mice bearing orthotopic U87MG-Luc tumors were divided into 6 groups, with 5 mice in each group. The six groups mainly included PBS, PBS+L, LET-12', LET-12'+L, LET-12 and LET-12+L. The PBS, LET-12' and LET-12 groups were only injected intravenously with PBS, LET-12' and LET-12. Meanwhile, the PBS+L, LET-12'+L and LET-12+L groups were first injected intravenously with PBS, LET-12' and LET-12, and 12 hours later, the mice were illuminated by 1064 laser (0.6W cm -2 ) for 5 min. After photothermal treatment, the activity of U87MG cells was monitored by a bioluminescent imaging system, which enabled real-time monitoring of tumor volume changes. Body weight changes were recorded every two days. Tumors were then collected and stained with TUNEL to assess the biosafety of the material and the efficacy of PTT. Fig.12 The survival rate of mice during treatment is shown in Figure 1. Fig.12 As shown in Figure 2; the changes in the spontaneous luminescence intensity of the original brain glioma in mice after photothermal treatment are shown in Figure 2. Fig.12 Figure 3 shows the TUNEL staining of tumors after mouse treatment. Fig.12 As shown in Figure 4, from the above results, it can be seen that the spontaneous luminescence intensity of mice in the LET-12+L group was significantly reduced after photothermal treatment compared with mice in other treatment groups, proving that LET-12 is enriched inside the tumor and has good photothermal properties, which can achieve photothermal treatment of tumors.
[0091] The nano-diagnostic and therapeutic agent (LET-12) described in the present invention can realize photothermal therapy guided by NIR-II multimodal imaging of in situ brain glioma.
[0092] In the present invention, the LET-12 has good clinical application prospects. MPC is a drug that has been reported to cross the blood-brain barrier, and LET-12' is also a rare molecule with a maximum emission at 1400nm NIR-IIb. After combining MPC with LET-12', LET-12' can be delivered to cross the blood-brain barrier and target the tumor, and the NIR-IIb window imaging of deep-seated tumors can be achieved.
[0093] The present invention has the following advantages: the nano-diagnostic agent LET-12 prepared by the preparation method of the present invention can be used for multimodal imaging and guided photothermal therapy of deep-seated tumors in the NIR-IIb window, and will have good application prospects in the field of tumor imaging and treatment. At the same time, the preparation process of the present invention is simple, easy to operate, does not require complex and expensive equipment, and is easy to achieve industrial production.
[0094] It should be understood that the application of the present invention is not limited to the above examples. For ordinary technicians in this field, improvements or changes can be made based on the above description. All these improvements and changes should fall within the scope of protection of the claims attached to the present invention.
Claims
1. A nano diagnostic and therapeutic agent, characterized in that: include: A J-type aggregate of a small molecule cyanine dye IR-1064, and a polymer bound to the surface of the J-type aggregate of the small molecule cyanine dye IR-1064, wherein the polymer is obtained by in-situ polymerization of acrylamide and 2-methacryloyloxyethyl phosphorylcholine on the surface of the J-type aggregate of the small molecule cyanine dye IR-1064, and the structural formula of the small molecule cyanine dye IR-1064 is as follows:
2. The nano diagnostic and therapeutic agent according to claim 1, characterized in that: The J-type aggregate of the small molecule cyanine dye IR-1064 and the polymer are combined by electrostatic interaction.
3. The nano diagnostic and therapeutic agent according to claim 1, characterized in that The nano-diagnostic and therapeutic agent is a spherical particle with a diameter of 50±4nm.
4. The nano diagnostic and therapeutic agent according to claim 1, characterized in that The surface of the nano-diagnostic agent is positively charged.
5. A method for preparing the nano diagnostic and therapeutic agent according to any one of claims 1 to 4, characterized in that: Includes steps: The small molecule cyanine dye IR-1064 is self-assembled to form a J-type aggregate of the small molecule cyanine dye IR-1064; The acrylamide and 2-methacryloyloxyethyl phosphorylcholine are made to undergo in-situ polymerization reaction on the surface of the J-type aggregate of the small molecule cyanine dye IR-1064 to obtain the nano diagnostic and therapeutic agent.
6. The method according to claim 5, characterized in that The preparation method of the nano diagnostic and therapeutic agent specifically comprises the steps of: The small molecule cyanine dye IR-1064 is dissolved in a mixed solution consisting of water and dimethyl sulfoxide, wherein the volume proportion of dimethyl sulfoxide in the mixed solution is 4%, and the mixture is first stirred under heating conditions, and then first centrifuged to obtain a J-type aggregate of the small molecule cyanine dye IR-1064; Acrylamide, 2-methacryloyloxyethyl phosphorylcholine and the J-type aggregate of the small molecule cyanine dye IR-1064 are mixed in water, and then ammonium persulfate and tetramethylethylenediamine are added under a second stirring to carry out an in situ polymerization reaction on the surface of the J-type aggregate of the small molecule cyanine dye IR-1064, and finally the nano-diagnostic and therapeutic agent is obtained through a second centrifugation.
7. The method according to claim 6, characterized in that The temperature of the in-situ polymerization reaction is 4° C., and the time of the in-situ polymerization reaction is 2.5 h; The mass ratio of the small molecule cyanine dye IR-1064, acrylamide, ammonium persulfate, tetramethylethylenediamine and 2-methacryloyloxyethyl phosphorylcholine is 1:0.05-0.1:0.1-0.5:0.1-0.5:1-5.
8. The method according to claim 6, characterized in that The heating temperature is 60°C; The speed of the first stirring is 500 rpm; the speed of the first centrifugation is 4500 rpm, and the centrifugation time is 15 min.
9. The method according to claim 6, characterized in that The mixing method is vortexing; The speed of the second stirring is 500 rpm; The second centrifugation speed is 4500 rpm and the centrifugation time is 15 min.
10. Use of the nano-diagnostic and therapeutic agent as described in any one of claims 1 to 4 or the nano-diagnostic and therapeutic agent prepared by the method described in any one of claims 5 to 9 in the preparation of a tumor diagnosis and treatment preparation.
